C hronic thromboembolic pulmonary hypertension (CTEPH) is caused by chronic stenosis or obstruction of the pulmonary arteries because of organized thrombi. 1 The only potentially curative treatment for CTEPH is pulmonary endarterectomy (PEA). Background-Balloon pulmonary angioplasty (BPA) is an alternative therapy for patients with chronic thromboembolic pulmonary hypertension who are ineligible for pulmonary endarterectomy-the standard therapy. Currently, most reported results of BPA are from relatively small cohorts treated at single centers. The present study evaluated the safety and efficacy of BPA for chronic thromboembolic pulmonary hypertension based on a multicenter registry. Methods and Results-A total of 308 patients (62 men and 246 women; mean age, 61 years) underwent 1408 procedures at 7 institutions in Japan. Data were retrospectively reviewed to evaluate clinical outcome and complications. Hemodynamics were significantly improved in 249 patients in whom BPA was terminated, most often because of improvement in mean pulmonary arterial pressure or symptomatic improvement after 1154 procedures. In 196 patients who underwent followup right heart catheterization, improvement of hemodynamic parameters was maintained. Mean pulmonary arterial pressure decreased from 43.2±11.0 to 24.3±6.4 mm Hg after final BPA and 22.5±5.4 mm Hg at follow-up, with significant reduction of concomitant use of pulmonary hypertension-targeted therapy and oxygen supplementation. Complications occurred in 511 (36.3%), including pulmonary injury (17.8%), hemoptysis (14.0%), and pulmonary artery perforation (2.9%). Twelve patients (3.9%) died during follow-up, including 8 patients who died within 30 days after BPA. The leading causes of death were right heart failure, multiorgan failure, and sepsis. Overall survival was 96.8% (95% confidence interval, 93.7%-98.4%) at 1 and 2 years and 94.5% (95% confidence interval, 89.3%-97.3%) at 3 years, respectively, after the initial BPA procedure for all 308 patients. Conclusions-This multicenter registry suggested improved hemodynamic results after BPA. Complication rates were high, but overall survival was comparable with pulmonary endarterectomy. BPA may be an important therapeutic option in patients with chronic thromboembolic pulmonary hypertension. (Circ Cardiovasc Qual Outcomes. 2017;10:e004029.
Multicenter Registry of BPA for CTEPH pulmonary angioplasty (BPA) was first reported in 1988 as an alternative treatment for a patient with CTEPH who was ineligible for PEA. 4 In 2001, a series of patients who underwent BPA was reported. 5 However, because of issues with efficacy and safety, BPA could not be recommended as an effective treatment for these patients. After 2012, the efficacy of BPA in improving hemodynamics and exercise capacity was established by case series reported by several groups. [6] [7] [8] [9] [10] Treatment guidelines now list BPA as an alternative option for patients with CTEPH who are ineligible for PEA. 2 However, most of the currently available reports are results from relatively small cohorts treated at single centers. Therefore, this study aimed to evaluate the efficacy and safety of BPA in a multicenter registry.
Methods

Patient Selection
Patients with CTEPH who underwent BPA at 7 institutions in Japan (Tohoku University, Tokyo University, Kyorin University, Mie University, National Cardiovascular Research Center, Kobe University, and National Hospital Organization Okayama Medical Center) between November 2004 and March 2013 were registered. These are the centers where BPA was performed when this project was initiated in 2011. During this time period, 7 participating centers initiated BPA programs, and all patients who underwent BPA were enrolled. The present study was approved by the institutional review board of each institution. A diagnosis of CTEPH was based on detailed medical history, physical examination, chest radiography, chest computed tomography, transthoracic echocardiography, lung ventilation-perfusion scintigraphy, right heart catheterization, and angiographic demonstration of multiple stenoses and obstructions of the bilateral pulmonary arteries.
1,2 All patients were referred to experienced surgeons for evaluation of operability.
Data Collection
Data were obtained from chart review, including medical history, comorbidities, World Health Organization (WHO) functional class, exercise tolerance, laboratory data, hemodynamic parameters, and treatment. Regarding BPA, the number of the procedures, complications, and reason for BPA termination were also collected. BPA termination was most often because of improvement in mean pulmonary arterial pressure (PAP) or symptomatic improvement.
Survival
The follow-up period for monitoring patient survival ended in March 2014. The primary end point for survival analysis was all-cause death. Long-term survival from the initial BPA procedure and the final BPA procedure were evaluated. Patients without follow-up catheter data were censored at day 1 of follow-up.
Statistical Analysis
Descriptive data are expressed as mean±SD for continuous variables. Categorical values are expressed as numbers and percentages or medians and ranges. The differences in WHO functional class, home oxygen therapy, warfarin, and pulmonary arterial hypertension-(PAH) targeted therapy among 3 time points (before BPA, after final BPA, and follow-up) were analyzed by marginal model with generalized estimating equation and Tukey post hoc test. Variables other than those described above were analyzed by linear mixed modeling and Tukey post hoc test. Survival analyses were conducted using the Kaplan-Meier method. All analyses were performed with SAS Release 9.4 (SAS Institute, Inc, Cary, NC). Statistical significance was defined as P<0.05.
Results
Patient Characteristics
Three hundred and eight patients with CTEPH who underwent BPA at 7 institutions were registered. Patient characteristics at study enrollment are summarized in Table 1 . Eighty percent of patients were women. Deep vein thrombosis was observed in one third of patients. Previous episode of acute pulmonary embolism was confirmed in only 15.3% of patients. The comorbidities and medical conditions recognized to be associated with pulmonary embolism and CTEPH were also evaluated but were only present in a low percentage of patients. Less than 10% of patients had thrombotic risk factors, including antiphospholipid syndrome (3.9%), protein C deficiency (2.6%), and protein S deficiency (2.3%). Approximately 9% of total patients (n=308; 10.8% of female patients [n=249]) had gynecologic disorders, including myoma uteri or ovarian cyst occupying the pelvic cavity. Psychiatric disorder was present in 7.1% of patients, 19.8% of patients reported regular alcohol consumption, and 24.7% of patients had smoking habits.
All patients were evaluated for eligibility for PEA before they underwent BPA. The decision and reasons for choosing BPA are shown in Table 2 . Fourteen patients (4.5%) had already undergone PEA, and the risk of reoperation was considered to be high. Seventy-six percent of patients were diagnosed to have inaccessible lesions. Approximately 20% of patients were considered to have accessible lesions. Among them, 18 patients (5.8%) were considered to have unfavorable risk/benefit ratio based on comorbidities or older age. The remaining patients refused surgical treatment and chose BPA.
Treatments patients received at enrollment are summarized in Table 3 . More than 70% of patients were on home oxygen therapy before BPA. Overall, 222 patients (72.1%) were on at least 1 PAH-targeted therapy.
WHAT IS KNOWN
• Balloon pulmonary angioplasty is emerging as an alternative therapy for patients with chronic thromboembolic pulmonary hypertension.
WHAT THE STUDY ADDS
• The first multicenter registry confirmed hemodynamic improvement after balloon pulmonary angioplasty.
• Hemodynamic improvement was maintained at follow-up with significant reduction of concomitant use of pulmonary hypertension-targeted therapy and oxygen supplementation.
• The complication rate is not low, but the survival rate was comparable with that of pulmonary endarterectomy.
• Balloon pulmonary angioplasty may be a safe and effective therapeutic option in patients with chronic thromboembolic pulmonary hypertension. Multicenter Registry of BPA for CTEPH
BPA Procedure
In the study period, a total of 1408 procedures were performed in all patients with a median of 4 procedures per person (range, 1-24 procedures per person). Among them, BPA was terminated in 249 patients with a total of 1154 procedures. These patients underwent a median of 4 procedures per person (range, 1-24 procedures per person). Mean time from the first to the final procedure was 366.6±394.1 days. The reasons for BPA termination were as follows: improvement of mean PAP, 216 (70.1%); symptomatic improvement, 21 (6.8%); technical difficulty, 5 (1.6%); allergic reaction to contrast medium, 1 (0.3%); cerebral infarction, 1 (0.3%); and patient's rejection, 1 (0.3%).
Outcome of BPA
Patient's clinical and hemodynamic parameters are shown in Table 4 and Figure 1 . At baseline, the majority of patients were in WHO functional class III or IV. Patients' hemodynamic parameters represented severe disease status with high mean PAP and pulmonary vascular resistance.
At the time of BPA termination, WHO functional class, exercise tolerance, and plasma brain natriuretic peptide levels were significantly improved. Hemodynamic parameters, including mean PAP and cardiac index, significantly improved. We succeeded in decreasing mean PAP by ≈20 mm Hg to an absolute pressure of <25 mm Hg. All parameters were improved by BPA immediately after the final procedures.
One hundred ninety-six patients underwent follow-up catheter at a mean of 425.5±280.9 days after the final procedures. At follow-up, the improvement achieved by BPA was maintained. Pulmonary hemodynamics, including mean PAP, did not show any worsening. These results were further highlighted by the fact that use of oxygen support and PAHtargeted drugs was significantly reduced (Table 3) .
Complications
Complications related to BPA occurred in 511 procedures, which accounted for 36.3% of all procedures (n=1408; Table 5 ). Pulmonary injury (17.8%) and hemoptysis (14.0%) were frequent. Pulmonary injury was diagnosed when infiltration appeared after the BPA procedure on chest radiograph or computed tomographic scan. Pulmonary artery perforation, pulmonary artery dissection, and pulmonary artery rupture caused by the BPA procedure occurred in 3.4% of procedures.
Severe complications requiring tracheal intubation with mechanical ventilation occurred in 17 patients (5.5%). Nine patients required extracorporeal membrane oxygenation. Five patients were treated with embolization using a coil; a covered stent (JOSTENT GraftMaster, Abbott Vascular, Santa Clara, CA) was used in 3 patients (one of them reported elsewhere 11 ).
Survival
In total, 12 (3.9%) among 308 patients died. Eight patients (2.6%) died within 30 days after BPA. Three patients died from sepsis, 2 from multiorgan failure, and 2 from right heart failure. One patient died suddenly after discharge from successful final BPA because of unknown cause. Four patients died during the follow-up period. Two died from right heart failure, 1 from multiorgan failure, and 1 from septal myectomy for hypertrophic cardiomyopathy. Overall survival was 96.8% (95% confidence interval, 93.7%-98.4%) at 1 and 2 years and 94.5% (95% confidence interval, 89.3%-97.3%) at 3 years, respectively, after the initial BPA procedure for all 308 patients (Figure 2A ). Overall survival after the final procedure of BPA for 249 patients was 98.9% (95% confidence interval, 95.7%-99.7%) at 1, 2, and 3 years ( Figure 2B ).
Discussion
Here, we report the results of the first multicenter registry of patients undergoing BPA. This study included 308 initial cases from 7 institutions in Japan and confirmed favorable effects on hemodynamics with maintained efficacy at follow-up with significant reduction of concomitant treatment. Although the complication rate is not low (36.3%), only 5.5% of patients required mechanical ventilation. Eight BPA indicates balloon pulmonary angioplasty; and PEA, pulmonary endarterectomy. Multicenter Registry of BPA for CTEPH patients (2.6%) died within 30 days after BPA, and 4 more patients died during follow-up. Overall survival after the final procedure of BPA for 249 patients was 98.9% at 1, 2, and 3 years.
In agreement with previous reports on CTEPH from Japan, 12 our cohort consisted of a large number of female patients. There is a distinct difference compared with the studies from Western countries, where there is no sex difference in the patient population. 3 Previous episodes of acute pulmonary embolism and deep vein thrombosis were not frequent in our patients, as compared with reports from other countries (74.8% and 58.1%, respectively, in a European registry 3 ). Fewer Japanese patients were diagnosed with thrombophilic disorder in a previous report from Japan. 12 Only 8.8% of the patients in our study had thrombotic risk factors, as compared with >30% in the European registry. Furthermore, gynecologic and psychiatric disorders were frequent in our patients and may be predisposing factors for CTEPH. Although we do not have data on human leukocyte antigen types in the present study, it is suggested that certain human leukocyte antigen types may be involved in Japanese patients with CTEPH. 13, 14 These human leukocyte antigen types are rare in Western countries, and CTEPH in Japanese patients may occur based on different mechanisms than those reported previously. The different demographics compared with those of previously reported Western populations may be attributed to ethnic differences, or there might be a different subgroup of patients with stenotic lesions mainly located in distal pulmonary arteries.
In the present study, >80% of the patients were deemed inoperable because of the lesion or the unfavorable risk/benefit Values are expressed as mean±SD unless otherwise specified. P value in the right column indicates the P value among 3 data points. 6MWD indicates 6-minute walk distance; BNP, B-type natriuretic peptide; BPA, balloon pulmonary angioplasty; CI, cardiac index; HR, heart rate; mPAP, mean pulmonary artery pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SaO 2 , arterial oxygen saturation; SvO 2 , mixed venous oxygen saturation; and WHO FC, World Health Organization functional class. *P<0.001 and †P<0.01 versus before BPA in post hoc analysis. Multicenter Registry of BPA for CTEPH ratio. However, a majority of them may have been classified as operable by surgeons in Europe or the United States, where PEA has been offered widely. Approximately 14% of patients refused operative treatment. Although reasons for refusal were not asked in the present study, they might be one of the following: invasiveness of PEA itself, and some patients need to be hospitalized in remote institutions because there are a limited number of surgeons capable of performing PEA in Japan.
At study enrollment, a large number of our patients were on at least 1 PAH-targeted therapy, although none of the drugs were approved for CTEPH in Japan at the time of enrollment. Considering the fact that PAH-targeted drugs are proven to have no effects on patients with CTEPH 15 except for riociguat, 16 this high prescription rate suggests that there is a need for effective treatment for patients with CTEPH who are ineligible for PEA.
This multicenter registry confirmed the significant improvement in clinical and hemodynamic parameters with BPA, previously reported in single-center studies.
6-10 WHO functional class, exercise tolerance, and hemodynamic parameters were significantly improved. Not only immediately after BPA but also at follow-up, improvement in patient data was maintained. Cardiac index declined at follow-up compared with immediately after BPA, which may be related to the fact that PAH-targeted drugs were stopped in many patients at follow-up. However, cardiac index at follow-up was significantly higher compared with before BPA.
Among several complications, the incidence of pulmonary injury was high. Reperfusion pulmonary injury is the leading complication of PEA, and the incidence is reported to be ≈20%. 17 In our first report of BPA, apparent pulmonary injury occurred in 60%. 6 Pulmonary injury occurred at the area where pulmonary arteries were dilated and disappeared at a median of 4 days. We attempted to avoid injury of the pulmonary artery by passing the targeted lesion without vigorously pushing the guidewire or balloon catheter. After a learning curve, the occurrence of pulmonary injury Figure 1 . Change in parameters after balloon pulmonary angioplasty (BPA). Parameters before BPA (n=308), immediately after final BPA (n=249), and at follow-up (n=196) were compared. World Health Organization functional class (WHO FC; A), mean pulmonary arterial pressure (mPAP; B), cardiac index (CI; C), and pulmonary vascular resistance (PVR; D) were significantly improved immediately after final BPA, and the improvement was maintained at follow-up. Multicenter Registry of BPA for CTEPH decreased, and we now consider that pulmonary injury in BPA might occur after vascular injury. 18 However, the present study was initiated before we came to this conclusion. Complications were reported by each operator, and pulmonary injury was reported when infiltration appeared after BPA on chest radiograph or computed tomographic scan. This led to different complication rates reported from different centers. Since most of these complications are now considered a consequence of pulmonary vascular injury related to the procedure, we need to improve techniques to reduce the complication rate.
Eight patients (2.6%) died within 30 days after BPA. During follow-up, 12 patients (3.9%) died in total. The causes of death were mostly related to severe right heart failure because of CTEPH. In-hospital mortality of PEA is reportedly as low as 4.7% 19 and even lower in a high-volume single center. 20 Surgery decreases mortality with an estimated survival at 1, 2, and 3 years of 93%, 91%, and 89%, respectively.
21
Our data show comparable results to PEA, and BPA might be considered a treatment option for CTEPH.
In conclusion, the first multicenter registry in Japan demonstrated that BPA performed at experienced pulmonary hypertension centers is a safe and effective therapeutic option in patients with CTEPH who are unsuitable for PEA. Further investigation within a multicenter prospective study is needed to confirm these results.
Limitations
There are some limitations to this study. First, this study was conducted retrospectively at institutions only in Japan with a limited number of patients. The reasonability of our data should be confirmed within a global multicenter prospective study. Because of the limited number of patients, we could not analyze the data of each institution separately. Second, the rate of pulmonary injury may vary among institutions because computed tomographic evaluation after BPA was performed in a small number of centers. Third, details of the BPA procedure vary depending on the institute. The present data include all procedures from the initial introduction at each institute, and results may be different with more BPA experience.
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